Prasugrel is a novel platelet inhibitor used for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI.
More Information Supplier PagePramipexole is a dopamine agonist of the non-ergoline class indicated for treating early-stage Parkinson’s disease (PD) and restless legs syndrome (RLS).
More Information Supplier PagePramipexole is a dopamine agonist of the non-ergoline class indicated for treating early-stage Parkinson’s disease (PD) and restless legs syndrome (RLS).
More Information Supplier PagePramipexole is a dopamine agonist of the non-ergoline class indicated for treating early-stage Parkinson’s disease (PD) and restless legs syndrome (RLS).
More Information Supplier PagePramipexole is a dopamine agonist of the non-ergoline class indicated for treating early-stage Parkinson’s disease (PD) and restless legs syndrome (RLS).
More Information Supplier PagePramipexole is a dopamine agonist of the non-ergoline class indicated for treating early-stage Parkinson’s disease (PD) and restless legs syndrome (RLS).
More Information Supplier PagePP242 is a potent and selective mTOR inhibitor in both mTORC1 and mTORC2.
More Information Supplier PagePP242 is a potent and selective mTOR inhibitor in both mTORC1 and mTORC2.
More Information Supplier PagePLX4032 (Vemurafenib) also known as RG7204, Vemurafenib, R7204; RO5185426. PLX4032 is a B-raf inhibitor with an IC50 of 44 nM.
More Information Supplier PagePLX4032 (Vemurafenib) also known as RG7204, Vemurafenib, R7204; RO5185426. PLX4032 is a B-raf inhibitor with an IC50 of 44 nM.
More Information Supplier Page
